Effect of the Combined Administration of mTOR Inhibitor and Dopamine or Somatostatin Analogues in a Human Bronchial Neuroendocrine Cell Line

#532

Introduction: The mTOR inhibitor rapamycin (RAP) has been considered an anticancer agent. The role of dopamine and somatostatin in controlling cell secretion and proliferation in neuroendocrine tumors (NETs) is still unclear.

Aim(s): To: 1) evaluate the expression of dopamine D2 receptor (D2R) and somatostatin SSTR2 receptor in the human bronchial carcinoid cell line NCI-H727, and 2) test the effect of RAP, somatostatin analogues (SSA) and dopamine agonists (DA) on vitality, hormone secretion and downstream pathway in H727 cell line

Materials and methods: D2R and SSTR2 expression was demonstrated by western blot (WB) and immunofluorescence. Proliferation was tested by MTT whereas Chromogranin A (CgA) secretion by ELISA to test the effect of RAP, cabergoline (CAB) and octreotide (OCT) alone or in combination. The effect of drugs on cell signaling was assessed by WB.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Pivonello R, Sarnataro M, Cariati F, Pivonello C, Colao A,

Keywords: neuroendocrine tumor, mTOR inhibitors, dopamine agonists, somatostatin analogues,